Hualan biological engineering, inc. announced that its investee company, Hualan Gene Engineering Co., Ltd., obtained the "Pharmaceutical Registration Certificate" for Bevacizumab injection issued by the National Medical Products Administration on November 21, 2024. This pharmaceutical is mainly used for the treatment of advanced, metastatic, or recurrent non-small cell lung cancer, with a total domestic sales of approximately 10.7 billion yuan in 2023. The approval of Bevacizumab injection for the gene company will officially begin production and sales, which will have a positive impact on the company's future operation performance.